Ruhe Henricus G, Horikx Annemieke, van Avendonk Mariëlle J P, Groeneweg Bart F, Mulder Hans, Woutersen-Koch Hèlen
Radboudumc, afd. Psychiatrie, Nijmegen.
Contact: Henricus G. Ruhe (
Ned Tijdschr Geneeskd. 2020 Feb 17;164:D4004.
Interruption or abrupt discontinuation of the use of antidepressants may lead to withdrawal symptoms. These are most common with selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs).There is insufficient scientific evidence about the prevalence of antidepressant withdrawal symptoms and how to optimally discontinue antidepressants. The multidisciplinary document 'Discontinuation of SSRIs & SNRIs' offers a rationale and suggestions for the gradual tapering of these antidepressants. The following factors are consistently named as risk factors for the occurrence of withdrawal symptoms: (a) the patient experiences withdrawal symptoms in case of non-compliance or skipped doses; (b) a previous attempt to stop was unsuccessful; and (c) the patient is being treated with higher doses than the smallest effective dose of SSRIs or SNRIs. In patients with one or more risk factors, a tapering schedule with non-linear dose-reduction steps should be considered. The speed at which these steps are taken, should be adjusted depending on occurrence of withdrawal symptoms. Shared decision-making by patient and physician is the best way to select a tapering schedule.
中断或突然停止使用抗抑郁药可能会导致戒断症状。这些症状在选择性5-羟色胺再摄取抑制剂(SSRI)和5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)中最为常见。关于抗抑郁药戒断症状的发生率以及如何最佳地停用抗抑郁药,目前尚无足够的科学证据。多学科文件《停用SSRI和SNRI》为这些抗抑郁药的逐渐减量提供了理论依据和建议。以下因素一直被认为是出现戒断症状的风险因素:(a)患者在不依从或漏服药物时出现戒断症状;(b)之前的停药尝试未成功;(c)患者正在接受高于SSRI或SNRI最小有效剂量的治疗。对于有一个或多个风险因素的患者,应考虑采用非线性剂量减少步骤的减量方案。采取这些步骤的速度应根据戒断症状的出现情况进行调整。患者和医生共同决策是选择减量方案的最佳方式。